I think the thought was that revenue from Vazalore would help them push forward the platform into pharma drug delivery. That is where the real value is. So getting to a significant % of ownership could give leverage if the company goes private. This stock is a case study in not knowing a consumer audience, and then fumbling with roll out price too high. I love the Vazalore product and have gone through a couple bottles, and am storing a couple in the cool basement. It's a cautionary tale to be applied to other small cap bio's especially. On a number of stocks I own or track, I still see people throwing out numbers for buyouts and deals based upon what was occurring a decade ago. I think better risk reward now is getting in later (just before approval) and just do stock with some just out of the money LEAPs. And too many are still having outsized hopes on early Phase trials to really jump a stock up to a much higher base. Different market now.
